216.73.216.231===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'cere'---select * from `0-usmeigara` WHERE code='cere'
aaセレベル セラピューティクス ホールディングス

cere
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
臨床段階のバイオ医薬品会社であるCerevel Therapeutics Holdings、Inc。同社の製品は、初期および後期パーキンソン病の治療のための第3相臨床試験である選択的ドーパミンD1/D5部分アゴニストであるタバパドンでも構成されています。また、精神病および関連する適応症の治療のためのM4アゴニストプログラムの開発にも関与しています。
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.」